Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis

BACKGROUND: Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and temsirolimus are now approved by regulatory agencies and have been widely investigated among various types of solid tumors, but the risk of fatal adverse events (FAEs) with these drugs is not well defined. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wei-Xiang, Huang, Yu-Jing, Yao, Yang, Shen, Zan, Min, Da-Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681778/
https://www.ncbi.nlm.nih.gov/pubmed/23785409
http://dx.doi.org/10.1371/journal.pone.0065166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681778/
https://www.ncbi.nlm.nih.gov/pubmed/23785409
http://dx.doi.org/10.1371/journal.pone.0065166

Ejemplares similares